Copyright
©The Author(s) 2020.
World J Clin Oncol. Aug 24, 2020; 11(8): 606-613
Published online Aug 24, 2020. doi: 10.5306/wjco.v11.i8.606
Published online Aug 24, 2020. doi: 10.5306/wjco.v11.i8.606
Table 3 Complete response rate among enroled patients
| Chemothrapycycle | Number of participants | Acute phase-number of participants (%) | Delayed phase-number of participants (%) | Overall phase-number of participants (%) |
| 1 | 75 | 73 (97.33) | 68 (90.66) | 68 (90.66) |
| 2 | 89 | 88 (98.87) | 86 (96.22) | 86 (96.22) |
| 3 | 30 | 28 (93.33) | 27 (90.00) | 27 (90.00) |
| 4 | 90 | 80 (88.88) | 75 (83.00) | 75 (83.00) |
| 5 | 52 | 52 (100.00) | 51 (98.07) | 51 (98.07) |
| > 5 | 67 | 65 (97.01) | 63 (94.02) | 63 (94.02) |
- Citation: Vaswani B, Bhagat S, Patil S, Barkate H. Effectiveness of a novel, fixed dose combination of netupitant and palonosetron in prevention of chemotherapy induced nausea and vomiting: A real-life study from India. World J Clin Oncol 2020; 11(8): 606-613
- URL: https://www.wjgnet.com/2218-4333/full/v11/i8/606.htm
- DOI: https://dx.doi.org/10.5306/wjco.v11.i8.606